Interim report of phase II study of new nitrosourea S 10036 in disseminated malignant melanoma.
J Natl Cancer Inst
; 80(17): 1407-8, 1988 Nov 02.
Article
in En
| MEDLINE
| ID: mdl-3172267
ABSTRACT
Thirty-three patients with disseminated malignant melanoma were entered in a phase II study of the new nitrosourea S 10036 using a 100-mg/m2 weekly induction schedule for 3-4 consecutive weeks. Patients who responded to this treatment were followed with a maintenance therapy every 3 weeks. Toxic effects were mainly hematological and consisted of delayed thrombocytopenia and leukopenia. Among 30 patients who could be evaluated, eight partial responses were observed (response rate, 26.67%); among seven patients with cerebral metastasis, two partial responses were observed. This multicentric study is currently being continued to confirm this interim report.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Melanoma
/
Antineoplastic Agents
Type of study:
Clinical_trials
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
J Natl Cancer Inst
Year:
1988
Type:
Article
Affiliation country:
France